SummaryA double-blind, placebo-controlled, cross-over clinical trial was performed to assess the effect of betahistine hydrochloride (Serc) in M6niere's disease. The diagnosis was based on paroxysmal attacks of rotational vertigo, with tinnitus, and a fluctuating sensori-neural deafness, together with the results of auditory and vestibular tests. Twenty-eight patients were admitted to the trial over 3 years. Twenty-two patients completed the trial. In total, they received betahistine 32 mg daily, for a period of 16 weeks, and placebo also for the same length of time, preceded in every case by a 4-week pre-treatment period. Daily symptom score cards were kept. There was a statistically significant improvement in favour of the drug with regard to vertigo, tinnitus and deafness. Vertigo was the most responsive symptom. No adverse reactions were observed.

No abstract

SUMMARY AND CONCLUSIONS Forty–six cases of carcinoma of the penis treated primarily by surgery were reviewed. The following conclusions were reached: Clinical staging as determined at the initial examination was of little value. Pathological division into “solid” or “cord” pattern was of great importance in selecting cases with a good (solid) or poor prognosis (cord). The degree of differentiation was of much less prognostic value. Urinary troubles were rare following a partial or radical amputation. There was little point in preserving penile length except for psychological reasons, as few cases were having regular sexual intercourse when their disease was diagnosed. We would like to thank Mr W. Keith Yeates of the Department of Urology, Newcastle General Hospital, for permission to include a number of his cases in this series.

No abstract